Publications: Media Center

Arterial Restenosis Clinical and Industry Overview - All New Release by The Next Phase Consultancy for Spring/Summer 2001

[Redmond, WA. September 5, 2001] Arterial restenosis following interventional treatment for coronary or peripheral artery disease continues to be a vexing clinical problem. An all-new restenosis market overview report is now available. The report is the second edition of a continuing publication examining the many modalities in use and in development for prevention and treatment of restenosis. “Coronary and Peripheral Artery Restenosis: Developments and Trends in Prevention and Treatment” is a Situational Market Analysis* (SMA*) Report published by The Next Phase* Consultancy. For the first time it is available to subscribers via the Internet at www.TheNextPhase.com. Web subscribers will receive free updates. The study can also be purchased as a conventional hardbound report.

“This report has grown to become a two-volume set due to its vast store of information. It continues to be the only one of its kind covering all the biomedical industries – pharmaceuticals, biotech and medical devices,” states Victoria Hunsicker Sanko, President of The Next Phase Consultancy, the study publisher. “We offer a variety of purchase options for this Spring/Summer 2001 edition, including a Winter 2001-2002 update at no extra charge to our online subscribers. Additional savings are available to our clients who purchase both the e-subscription and the hardbound two-volume set.”

The study contains a wealth of information including analysis of 135 technologies and 400 products from 160 companies and research institutions. “Coronary and Peripheral Artery Restenosis: Developments and Trends in Prevention and Treatment” consists of two volumes, the first comprising an industry overview and the second containing The Next Phase’s unique SMArt Chart* section. The complete study has more than 300 pages of information with over 45 figures and tables, a glossary of terms, and an alphabetical subject index. “One of the unique features of the report is the recently updated SMArt Chart volume which has grown to nearly 150 pages,” according to Hunsicker Sanko. “The SMArt Chart section is a quick, easy-to-use reference tool for comparison of over 400 globally available and developing restenosis therapies. It is organized in five sections by general modality.” The modalities include:

• Systemic Drug Delivery
• Local Drug Delivery
• Medical Devices
• Gene Therapy
• Other Advanced Therapies."

“Coronary and Peripheral Artery Restenosis: Developments and Trends in Prevention and Treatment” is targeted to Presidents and CEOs of development stage and biotechnology companies and managers of large biomedical companies with an interest in restenosis therapy. Customers include marketing, business development, and R&D executives in medical device, biotechnology, and pharmaceutical companies, venture capital companies and other consulting companies interested in interventional cardiology, interventional radiology, and coronary and peripheral artery disease.

For more information, including the Volume I “Core Report” Table of Contents, the Volume II “SMArt Chart” section Index, and ordering information, visit The Next Phase Consultancy’s Web Site at http://www.TheNextPhase.com or e-mail The Next Phase at .

Contact Personnel:
Victoria Hunsicker Sanko
President
Tel: 1-425-869-8724
Fax: 1-425-869-9397

Last modified February 18, 2004

SERVICES | EXPERIENCE | PUBLICATIONS | ABOUT US | OUTSIDE U.S.
Our Partners | Search | Contact | Privacy | Home

The Next Phase Consultancy, Inc.
Phone: 425.869.8724 / Fax: 425.869.9397
e-mail:

Trademark information:
The Next Phase and The Next Phase "Moons" logo are registered trademarks, and The Next Phase SMArt Chart, CPI, PTMA, SMA, TNP and TNP SMArt Chart are trademarks of The Next Phase Consultancy, Inc. Send mail to , with questions or comments about this web site.

Copyright © 2007 The Next Phase Consultancy, Inc. All rights reserved.